» Articles » PMID: 36457557

Glutamatergic System Components As Potential Biomarkers and Therapeutic Targets in Cancer in Non-neural Organs

Overview
Specialty Endocrinology
Date 2022 Dec 2
PMID 36457557
Authors
Affiliations
Soon will be listed here.
Abstract

Glutamate is one of the most abundant amino acids in the blood. Besides its role as a neurotransmitter in the brain, it is a key substrate in several metabolic pathways and a primary messenger that acts through its receptors outside the central nervous system (CNS). The two main types of glutamate receptors, ionotropic and metabotropic, are well characterized in CNS and have been recently analyzed for their roles in non-neural organs. Glutamate receptor expression may be particularly important for tumor growth in organs with high concentrations of glutamate and might also influence the propensity of such tumors to set metastases in glutamate-rich organs, such as the liver. The study of glutamate transporters has also acquired relevance in the physiology and pathologies outside the CNS, especially in the field of cancer research. In this review, we address the recent findings about the expression of glutamatergic system components, such as receptors and transporters, their role in the physiology and pathology of cancer in non-neural organs, and their possible use as biomarkers and therapeutic targets.

Citing Articles

A glutamatergic biomarker panel enables differentiating Grade 4 gliomas/astrocytomas from brain metastases.

Lange F, Gade R, Einsle A, Porath K, Reichart G, Maletzki C Front Oncol. 2024; 14:1335401.

PMID: 38835368 PMC: 11148222. DOI: 10.3389/fonc.2024.1335401.


Plasma Metabolite Profiling in the Search for Early-Stage Biomarkers for Lung Cancer: Some Important Breakthroughs.

Meynen J, Adriaensens P, Criel M, Louis E, Vanhove K, Thomeer M Int J Mol Sci. 2024; 25(9).

PMID: 38731909 PMC: 11083579. DOI: 10.3390/ijms25094690.


Whole-genome bisulfite sequencing identifies stage- and subtype-specific DNA methylation signatures in pancreatic cancer.

Wang S, Hall M, Lee E, Kim S, Ramesh N, Lee S iScience. 2024; 27(4):109414.

PMID: 38532888 PMC: 10963232. DOI: 10.1016/j.isci.2024.109414.


Bench-to-Bedside Studies of Arginine Deprivation in Cancer.

Field G, Pavlyk I, Szlosarek P Molecules. 2023; 28(5).

PMID: 36903394 PMC: 10005060. DOI: 10.3390/molecules28052150.


NMDA Receptor and Its Emerging Role in Cancer.

Gallo S, Vitacolonna A, Crepaldi T Int J Mol Sci. 2023; 24(3).

PMID: 36768862 PMC: 9917092. DOI: 10.3390/ijms24032540.

References
1.
Monyer H, Seeburg P, Wisden W . Glutamate-operated channels: developmentally early and mature forms arise by alternative splicing. Neuron. 1991; 6(5):799-810. DOI: 10.1016/0896-6273(91)90176-z. View

2.
Kang M, Cho J, Koo J, Noh S, Kim M, Kang H . The Expression of NMDA Receptor 1 Correlates with Clinicopathological Parameters in Cutaneous Squamous Cell Carcinoma. Ann Dermatol. 2010; 21(4):382-8. PMC: 2861274. DOI: 10.5021/ad.2009.21.4.382. View

3.
Sureda F, Copani A, Bruno V, Knopfel T, Meltzger G, Nicoletti F . Metabotropic glutamate receptor agonists stimulate polyphosphoinositide hydrolysis in primary cultures of rat hepatocytes. Eur J Pharmacol. 1998; 338(2):R1-2. DOI: 10.1016/s0014-2999(97)81950-4. View

4.
Waddell T, Miller T . Chemical evolution of the citric acid cycle: sunlight photolysis of the amino acids glutamate and aspartate. Orig Life Evol Biosph. 1991; 21(4):219-23. DOI: 10.1007/BF01809857. View

5.
Koga T, Naraoka H . A new family of extraterrestrial amino acids in the Murchison meteorite. Sci Rep. 2017; 7(1):636. PMC: 5428853. DOI: 10.1038/s41598-017-00693-9. View